[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335804-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335804-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comparison-of-tp53-mutations-in-myelodysplasia-and-acute-leukemia-suggests-divergent-roles-in-initiation-and-progression","Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression","","TP53 mutations in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) differ in their distribution and functional consequences, implying distinct biological roles in disease onset and progression. The study analyzed TP53 mutation patterns across four myeloid neoplasm subtypes, identifying variation in mutation types, spectra, and DNA-binding domain hot spots. Missense mutations in the DNA-binding domain were most common across categories, while inactivating and non-DNA-binding mutations were more frequent in AML-MRC than in MDS. MDS cases more often retained transcriptional activity, and comutation profiles differed by category and mutation type, supporting targeted TP53 identification in myeloid malignancies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comparison-of-tp53-mutations-in-myelodysplasia-and-acute-leukemia-suggests-divergent-roles-in-initiation-and-progression/335804/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comparison-of-tp53-mutations-in-myelodysplasia-and-acute-leukemia-suggests-divergent-roles-in-initiation-and-progression/335804.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do TP53 mutations differ between MDS and AML?","Question",{"text":63,"@type":64},"TP53 mutations show significantly different distribution and functional consequences in MDS versus AML, suggesting distinct roles in initiation versus progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What TP53 mutation patterns were most common across the subtypes?",{"text":68,"@type":64},"Missense mutations in the DNA-binding domain were the most common across all categories, with characteristic differences in other mutation types between subgroups.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are the findings important for clinical use?",{"text":72,"@type":64},"The results support the utility of specifically identifying TP53 mutations in myeloid malignancies, because mutated TP53 contributes to disease initiation and progression through distinct mechanisms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335804,1790156510,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","REGULAR ARTICLE  \n neoplasia  \nComparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression  \nAshwini Jambhekar, 1, 2 Emily E. Ackerman, 1 Berk A. Alpay,3, 4 Galit Lahav, 1, 2 and Scott B. Lovitch5  \n1 Department of Systems Biology, Harvard Medical School, Boston, MA; 2 Ludwig Center at Harvard, Boston, MA; 3 Systems, Synthetic, and Quantitative Biology Program and  \n4 Department of Organismal and Evolutionary Biology, Harvard University, Cambridge, MA; and 5 Department of Pathology, Brigham and Women’s Hospital, Boston, MA  \nKey Points  \n• TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia differ signiﬁcantly in distribution and functional consequences.  \n• These differences suggest distinct biological roles for mutated p53 in initiation of myeloid dysplasia and progression to acute leukemia.  \nTP53 mutation predicts adverse prognosis in many cancers, including myeloid neoplasms, but the mechanisms by which speciﬁc mutations affect disease biology, and whether they differ between disease categories, remain unknown. We analyzed TP53 mutations in 4 myeloid neoplasm subtypes (myelodysplastic syndrome [MDS], acute myeloid leukemia [AML], AML with myelodysplasia-related changes [AML-MRC], and therapy-related AML), and identiﬁed differences in mutation types, spectrum, and hot spots between disease categories and in comparison to solid tumors. Missense mutations in the DNA-binding domain were most common across all categories, whereas inactivating mutations and mutations outside the DNA binding domain were more common in AML-MRC than in MDS. TP53 mutations in MDS were more likely to retain transcriptional activity, and comutation proﬁles were distinct between disease categories and mutation types. Our ﬁndings suggest that mutated TP53 contributes to initiation and progression of neoplasia via distinct mechanisms, and support the utility of speciﬁc identiﬁcation of TP53 mutations in myeloid malignancies.  \nIntroduction  \nThe transcription factor p53, encoded by the TP53 gene, functions as a tumor suppressor in multiple tissues.1 TP53 is the most frequently mutated gene in human cancers, with mutation incidence exceeding 50% for many cancer types.2 In myeloid neoplasms, TP53 mutations occur in ~10% of cases,3,4 and, as for solid tumors, are strong and independent predictors of adverse prognosis, including failure of induction chemotherapy, relapse after hematopoietic stem cell transplantation, and reduced overall survival.5-8  \nMyeloid neoplasms have traditionally been divided into myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) by blast enumeration, with >20% blasts in the blood or bone marrow generally required for classiﬁcation as AML; this division persists in the current World Health Organization (WHO) classiﬁcation9 and International Consensus Classiﬁcation (ICC) .10 AML arising via progression from MDS, or after cytotoxic chemotherapy or radiation, have worse prognosis than de novo AML and are separately classiﬁed; these categories were deﬁned as AML with myelodysplasia-related changes  \nSubmitted 19 October 2023; accepted 8 February 2024; prepublished online 15 February 2024; final version published online 12 March 2024. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1016/j.bneo.2024.100004](10.1016/j.bneo.2024.100004.)[.](10.1016/j.bneo.2024.100004.)  \nPresented, in part, as a selected oral abstract at the United States and Canadian Academy of Pathology annual meeting, New Orleans, LA, 14 March 2023 .  \nData are available on request from the corresponding author, Scott B. Lovitch ([slovitch@bwh.harvard.edu](slovitch@bwh.harvard.edu)) .  \nThe online version of this article contains a data supplement.  \n© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4 . 0 International (CC BY-NC-ND 4 . 0), permitting only noncommercial, nonderivative use with attrib","cbCaihVgjeyemq6c","https://ap.wps.com/l/cbCaihVgjeyemq6c","pdf",1589543,11,"English","# Key points\n# Results\n## Mutation distribution and functional consequences\n## Mutation spectrum and hot spots\n# Introduction\n## Clinical relevance of TP53 mutations\n## Classification of myeloid neoplasms and TP53 impact","[{\"question\":\"How do TP53 mutations differ between MDS and AML?\",\"answer\":\"TP53 mutations show significantly different distribution and functional consequences in MDS versus AML, suggesting distinct roles in initiation versus progression.\"},{\"question\":\"What TP53 mutation patterns were most common across the subtypes?\",\"answer\":\"Missense mutations in the DNA-binding domain were the most common across all categories, with characteristic differences in other mutation types between subgroups.\"},{\"question\":\"Why are the findings important for clinical use?\",\"answer\":\"The results support the utility of specifically identifying TP53 mutations in myeloid malignancies, because mutated TP53 contributes to disease initiation and progression through distinct mechanisms.\"}]","Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression | PDF",1790012387,28]